TABLE 4.

Secondary outcomes at each time point in both groups

Parameter		Group 1	Group 2
% of variation in iCa at 3 months (±2 months)	Median	−12.3	−0.7	P = .37
	IQR	[−19.5; −2.8]	[−7.4; 3.5]
	n	10	5
% of variation in iCa at 6 months (±2 months)	Median	−17.8	−1.3	P = .35
	IQR	[−21.3; 3.2]	[−6.2; 3.3]
	n	9	7
% of variation in iCa at 9 months (±2 months)	Median	−5.0	−1.0	P = .34
	IQR	[−6.9; −5.0]	[−11.1; 1.8]
	n	4	4
% of variation in iCa at 12 months (±2 months)	Median	−13.8
	IQR	[−15.2; −6.1]
	n	6	0
% of variation in iCa between iCa t0 and minimal iCa	Median	−23.7	−7.4	P = .08
	IQR	[−27.2; 19.9]	[−13.9; −2.0]
	n	11	9
% of episodes of normocalcemia over the total number of follow‐up	Median	50.0	25.0	P = .20
	IQR	[21.8; 54.6]	[0; 50.0]
	n	11	9
% of days spent with normocalcemia over the total duration of follow‐up	Median	32.9	8.7	P = .11
	IQR	[10.7; 41.6]	[0; 20.2]
	n	11	9

Note: Entries where data are missing have been left blank. Group 1 refers to cats treated with alendronate, and Group 2 refers to cats that received other or no treatment.

Abbreviations: IQR, interquartile range; iCa, ionized calcium concentration.